Long-Term Follow-Up Data from Phase 3 Study of CAMZYOS (mavacamten) Underscores Established Efficacy and Safety Profile in Patients with Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM)

Bristol Myers Squibb reported new long-term follow-up results from the EXPLORER-LTE cohort of the MAVA-Long-Term Extension (LTE) study evaluating CAMZYOS (mavacamten) in adult patients with New York Heart Association (NYHA) [...]